GleamWall
中文EN

TLSA Tiziana Life Sciences Ltd IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723069 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY32.9%
TTM EPS YoY35.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-250.5%
ROA-101.1%
ROIC (approx.)-546.6%
Asset turnover—

Leverage & solvency

Liabilities / assets65.1%
Debt / equity0.00x
Current ratio1.02x
Interest coverage-8.94x

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-88.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY2024*2024-12-31FY2023*2023-12-31
Income statement
Revenue——
R&D expense$5.23M$8.11M
Operating income-$15.79M-$17.98M
Interest expense$1.77M$412,000
Pretax income-$16.75M-$17.24M
Income tax-$4.88M$449,000
Net income-$11.86M-$17.69M
EPS (basic)-0.11-0.17
EPS (diluted)-0.11-0.17
Balance sheet
Cash & equivalents$3.72M$1.18M
Current assets$7.51M$7.34M
PP&E, netmay include right-of-use assets (IFRS)$16,000$10,000
Total assets$11.28M$12.18M
Current liabilities$7.35M$6.54M
Total liabilities$7.35M$6.65M
Shareholders' equity$3.94M$5.54M
Cash flow statement
Operating cash flow-$1.53M-$15.70M
Capital expenditure$19,000—
Free cash flow-$1.54M—
Investing cash flow-$71,000-$1.25M
Financing cash flow$4.50M$40,000
Stock-based compensation$910,000$1.73M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.